MedSurg solutions
Revenue Exposure
MedSurg is the largest segment at 57.9% of 2025 total sales, driven by wound care, infection prevention, and surgical supplies demand.
Relevance 95·Dependency 90·Confidence 98
Source evidence
“MedSurg (57.9% of 2025 total sales) is a provider of solutions including negative pressure wound therapy”
3M is the sole source of supply for raw materials used in certain Solventum products; failure of 3M to supply would harm the business.
Relevance 95·Dependency 85·Confidence 97
Source evidence
“3M is the sole source of supply for raw materials used in certain of our products and our business will be harmed if 3M does not satisfy our requirements.”
Hospitals and clinics/practices
Customer Exposure
All three segments serve healthcare providers from multidisciplinary hospitals to local clinics/practices; long-tenured relationships drive retention.
Relevance 85·Dependency 80·Confidence 94
Source evidence
“We serve a diverse customer base, ranging from multidisciplinary hospitals to local clinics/practices.”
MedSurg segment
Revenue Exposure
MedSurg is the largest segment with FY2025 sales of $4,817M (58% of total), growing 3.9% reported / 3.5% organic
Relevance 85·Dependency 75·Confidence 97
Source evidence
“MedSurg4,817 4,637 3.9 0.6 3.3 (0.2)3.5”
Medical product regulations
Legal Exposure
Products are regulated in most served markets; compliance failures can trigger recalls, fines, license revocation and criminal prosecution.
Relevance 85·Dependency 70·Confidence 95
Source evidence
“Solventum commits a significant amount of resources to maintain compliance with these regulations and standards”
Changing demographics
Demand Driver
Aging population and chronic conditions drive demand for Solventum's healthcare solutions
Relevance 85·Dependency 60·Confidence 93
Source evidence
“An aging population, the prevalence and incidence rates of chronic conditions, and a rising middle class are driving the demand for improved access to quality care.”
3M indemnifies Solventum for certain PFAS liabilities only through 2025 product sales; after 2025 Solventum bears PFAS-related regulatory and litigation exposure and lost 3M PFAS supply.
Relevance 85·Dependency 60·Confidence 95
Source evidence
“3M ceased supplying Solventum with PFAS-related products or components at the end of 2025.”
PFAS liabilities
Legal Exposure
Potential PFAS-related liabilities could adversely impact results of operations.
Relevance 85·Dependency 50·Confidence 90
Source evidence
“Solventum may face potential liabilities related to PFAS, which could adversely impact Solventum’s results.”
Healthcare providers and payers
Demand Driver
Reimbursement constraints push providers/payers to reduce avoidable administrative costs, driving demand for Solventum workflow optimization solutions
Relevance 80·Dependency 65·Confidence 90
Source evidence
“As healthcare providers and payers face increasing reimbursement constraints and evolving payment models, the need to reduce avoidable administrative costs has become more acute.”
Ongoing commercial relationships with 3M remain significant post-Spin-Off and could adversely affect the business and stock price.
Relevance 80·Dependency 60·Confidence 90
Source evidence
“Following the Spin-Off, Solventum’s commercial relationships with 3M remain significant, which could adversely affect Solventum’s business”
PFAS restrictions
Regulatory Exposure
Accelerating global PFAS restrictions and litigation create material risk for products containing or enabled by PFAS after the 3M indemnification window ends.
Relevance 80·Dependency 50·Confidence 92
Source evidence
“There have been accelerating regulatory and legislative activities concerning PFAS globally, including increasingly strict restrictions on various uses of PFAS in products, as well as increased litigation relating to PFAS”
Purification and Filtration business
Revenue Exposure
P&F divested September 2025 to Thermo Fisher for ~$4B; segment sales fell 29.9% to $497M, driving -3.0% 'other' sales impact
Relevance 80·Dependency 0·Confidence 95
Source evidence
“Purification and Filtration497 709 (29.9)1.1 (31.0)(36.5)5.5”
AI and digital care delivery
Demand Driver
Shift toward digitally enabled, AI-supported care drives demand for Solventum's integrated digital solutions
Relevance 78·Dependency 55·Confidence 90
Source evidence
“Whether it is interactions with patients through a digital interface or the use of data, analytics, and artificial intelligence (AI) to support informed health decisions, the need for digital tools in the healthcare industry has grown over time.”
Separation debt service
Cost Driver
Debt incurred in separation adversely affects profitability and constrains cash deployment; cost of servicing debt is a risk to market opportunities
Relevance 75·Dependency 70·Confidence 90
Source evidence
“the cost to service the debt we incurred in connection with the separation”
Health Information Systems software
Revenue Exposure
HIS contributed 16.3% of 2025 total sales via healthcare software for revenue cycle and clinician productivity.
Relevance 75·Dependency 65·Confidence 97
Source evidence
“Health Information Systems (16.3% of 2025 total sales) provides healthcare systems with software solutions”
Healthcare regulation
Regulatory Exposure
Solventum operates in a strictly regulated industry; compliance is costly and failures may result in significant penalties.
Relevance 75·Dependency 55·Confidence 85
Source evidence
“Solventum operates in a strictly regulated industry, and compliance with laws and regulations applicable to the commercialization of Solventum’s products is costly and failure to comply may result in significant penalties.”
AI-enabled competition
Competitive Exposure
AI-enabled competitors and disruptive technologies pose business model disruption risk, particularly for the HIS business, affecting demand and pricing.
Relevance 75·Dependency 45·Confidence 93
Source evidence
“the emergence of new AI-enabled competitors and business model disruption, particularly for our HIS business”
Lower-cost care sites (ASCs, wound clinics, retail pharmacies, home)
Demand Driver
Shift of care from hospitals to lower-cost alternative sites drives demand for Solventum solutions across care settings
Relevance 72·Dependency 50·Confidence 88
Source evidence
“Alternative care sites, such as ambulatory surgery centers, wound care clinics, retail pharmacies, and the home, are more affordable and accessible to patients.”
Interest rates
Cost Driver
With ~$5 billion of debt, changes in interest rates could adversely affect Solventum; credit rating changes could raise funding costs.
Relevance 70·Dependency 65·Confidence 90
Source evidence
“Changes in foreign currency exchange rates or interest rates could adversely affect Solventum.”
Dental Solutions products
Revenue Exposure
Dental Solutions contributed 16.2% of 2025 total sales via dental and orthodontic products.
Relevance 70·Dependency 60·Confidence 97
Source evidence
“Dental Solutions (16.2% of 2025 total sales) is a provider of a comprehensive suite of dental and orthodontic products”
Third-party payers
Demand Driver
Changes in third-party payer reimbursement practices and cost containment measures could affect demand and pricing for products.
Relevance 70·Dependency 60·Confidence 85
Source evidence
“Changes in reimbursement practices of third-party payers or other cost containment measures or worsening economic conditions could affect the demand for Solventum’s products and the prices at which they are sold.”
US Dollar
Currency Exposure
USD-denominated statements with material non-US revenues mean USD strength could reduce reported sales and earnings growth.
Relevance 70·Dependency 55·Confidence 93
Source evidence
“particularly if the value of the U.S. dollar strengthens significantly against foreign currencies”
Smith & Nephew
Competitive Exposure
Smith & Nephew is a principal competitor in the highly competitive advanced wound care market, particularly in the US and Europe.
Relevance 70·Dependency 55·Confidence 95
Source evidence
“the advanced wound care market is highly competitive, particularly in the United States and Europe, with our principal competitors including Smith & Nephew, Medaxis, Mölnlycke, Coloplast, and Convatec.”
Tax Matters Agreement
Tax Exposure
Tax-free treatment of the spin-off depends on compliance with Tax Matters Agreement restrictions on equity transactions and business changes for two years post-distribution.
Relevance 70·Dependency 55·Confidence 90
Source evidence
“To preserve the tax-free treatment of the distribution and certain related transactions, and in addition to Solventum’s indemnity obligation described below, the Tax Matters Agreement restricts Solventum, for the two-year period following the distribution”
Spin-Off from 3M: loss of brand benefits, 3M India retained businesses create divestiture sales headwinds, and ongoing supply agreements with 3M contribute sales
Relevance 70·Dependency 55·Confidence 88
Source evidence
“certain health care businesses retained by 3M India in connection with the Spin-Off, as well as impacts from other immaterial divested businesses”
Environmental, Health and Safety laws and regulations
Regulatory Exposure
EHS permitting, licensing, emissions, and hazardous materials rules affect a significant portion of activities globally across each segment.
Relevance 65·Dependency 60·Confidence 90
Source evidence
“These affect a significant portion of our activities globally across each of our segments and product lines and require compliance”
Foreign currency exchange
Currency Exposure
Changes in foreign currency exchange rates could adversely affect results; repatriation of earnings could trigger withholding taxes raising the effective tax rate.
Relevance 60·Dependency 50·Confidence 85
Source evidence
“requiring Solventum to repatriate earnings to the U.S., causing withholding taxes to be applied, which in turn could increase Solventum’s effective tax rate; and”
EU Corporate Sustainability Reporting Directive
Regulatory Exposure
CSRD and similar climate/sustainability reporting mandates increase compliance burdens and costs for Solventum and its supply chain.
Relevance 60·Dependency 35·Confidence 88
Source evidence
“Solventum and companies in its supply chain may experience increased compliance burdens and costs to meet the regulatory obligations”
Dentsply Sirona
Competitive Exposure
Dentsply Sirona is a principal multinational competitor in dental and orthodontic solutions.
Relevance 55·Dependency 45·Confidence 95
Source evidence
“Principal multinational competitors within the oral care market include Dentsply Sirona, Envista, and Straumann”
Climate policy and carbon costs
Cost Driver
Carbon taxes, cap-and-trade, and sterilization/disposal climate-related costs could raise Solventum's cost structure and shift customer demand.
Relevance 55·Dependency 30·Confidence 85
Source evidence
“imposing climate-related costs associated with product sterilization, disposal, or recycling; and/or imposing an economic cost on carbon such as through carbon taxes or cap-and-trade systems”